UK Markets open in 20 mins

Sanofi (SNYNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
112.50+10.35 (+10.13%)
At close: 11:40AM EDT
Sign in to post a message.
  • F
    Frank
    Hello I'm new in bitcoin and i have been making huge losses but i recently see a lot of people earning from it. Can someone please tell me what I'm doing wrong
  • j
    james
    Will we drop $1.80 tomorrow?
  • S
    Scott
    Any reason for the huge drop?
  • L
    Leanne
    Next catalysts?
  • s
    steve
    U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal
  • l
    letmebehonest
    Sanofi to open big multi vaccine manufacturing in Singapore as per local news, this is great news for Singapore and all investors....check the news feed about this info. Sanofi is the future of Bio Pharma manufactiring
  • J
    Joe
    besides the polio vaccine what French company has ever offered any good stock that makes investors money?
  • A
    ASAP
    President of the US just mentioned hydroxychloroquine ! Developed dby Sanofi and Regeneron Pharmaceuticals, Inc
  • P
    Priscilla
    ⭐ Top Bullish Charts | January 2022 💰💵📈

    https://chart-analysis.tools/Bullish-Charts
  • L
    Laxmoji
    Breaking news! Buy NVAX share ASAP. It is currently at $180 will touch $350 in just 4 days! EU approval is expected at any time. many approvals( UK, India, Canada, WHO) are on the way in 10 days! Shares are sky rocketing.

    Novavax surges on the news European nod for COVID-19 shot is imminent
    Novavax COVID-19 vaccine could be approved very soon, says EMA chief
    REUTERS 8:16 AM ET 12/7/2021

    BRUSSELS, Dec 7 (Reuters) - The head of the European Medicines Agency (EMA) on Tuesday said that it could soon approve the COVID-19 vaccine developed by U.S. biotech company Novavax(NVAX).

    "The vaccine from Novavax(NVAX) could be authorised in the very near future," Emma Cooke told EU health ministers during a public session of a meeting in Brussels. (Reporting by Francesco Guarascio Editing by David Goodman )
  • B
    BULL OF BAY STREET
    just got funding from canadian govt to build vaccine facility in toronto. heard it here first
  • n
    nito
    Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial. $SNY, $PFE, $JNJ, $EBS, $AZN, $NVS, $GSK
    Trial also achieves statistical significance in key secondary endpoints
    Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway
    Company to host investor conference call today at 8:30 a.m. EDT
    GAITHERSBURG, Md., March 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, in adults aged 65 and older. Using the Food and Drug Administration’s (FDA) criteria for accelerated approval of seasonal influenza vaccines, the trial evaluated the immunogenicity and safety of NanoFlu compared to Fluzone® Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.
    https://finance.yahoo.com/news/novavax-nanoflu-achieves-primary-endpoints-100010015.html
  • M
    Madeleine
    Breaking : Ontario (CAN) to build vaccine facility
  • N
    Nuno
    I think that sanofi in undervalued. From my calculations the target price is 93#$%$ however i'm not taking into consideration the molecules pipeline and assuming that dupixent dont lose market share.Please share your opinions.This post is not a recomendation.
  • H
    H
    Sanofi SA will be able to provide millions of doses of hydroxychloroquine for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive told Reuters on Thursday.
    Sanofi SA will be able to provide millions of doses of hydroxychloroquine for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive told Reuters on Thursday.
    www.reuters.com
  • s
    scott
    Enrolled 150 patients - focused on high risk population. Interviewing Dr. who’s leading study on GMA now.
  • R
    Rami
    The government is looking into Hydroxychloroquine (HCQ) sold under the brand name Plaquenil as a therapeutic treatment for COVID19. Who owns Plaquenil? Yep, Sanofi.

    French pharmaceutical company Sanofi said on Wednesday that it is ready to offer the French authorities the anti-malarial drug in the fight against the new coronavirus killing thousands worldwide.
    In a recent clinical trial, the Plaquenil drug was tested on 24 patients, and after six days, the virus had disappeared in three quarters of them
  • G
    Goldfinger
    Drugmaker Sanofi raises 2021 profit guidance again after Q3 beat
  • n
    nito
    Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May $PFE, $JNJ, $GSK, $AZN, $NVS, $GILD, $EBS
    -- NVX-CoV2373 identified as SARS-CoV-2 candidate for Phase 1 clinical trial
    -- In preclinical studies, NVX-CoV2373 demonstrated high immunogenicity and stimulated high levels of neutralizing antibodies
    -- First-in-human Phase 1 clinical trial accelerated to mid-May with preliminary results in July
    -- GMP clinical production initiated at Emergent BioSolutions with ability to leverage capacity for large scale manufacturing
    GAITHERSBURG, Md., April 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’ proprietary Matrix-M™ adjuvant will be incorporated with NVX-CoV2373 in order to enhance immune responses and stimulate high levels of neutralizing antibodies.
    NVX-CoV2373 was shown to be highly immunogenic in animal models measuring spike protein-specific antibodies, antibodies that block the binding of the spike protein to the receptor and wild-type virus neutralizing antibodies. High levels of spike protein-specific antibodies with ACE-2 human receptor binding domain blocking activity and SARS-CoV-2 wild-type virus neutralizing antibodies were observed after a single immunization. In addition, the already high microneutralization titers seen after one dose increased eight fold with a second dose. High titer microneutralizing antibodies are generally accepted evidence that a vaccine is likely to be protective in humans.
    https://finance.yahoo.com/news/novavax-identifies-coronavirus-vaccine-candidate-100010906.html
  • n
    nito
    Mymetics (MYMX) and Sanofi Pasteur, vaccine unit of Sanofi (SNY) collaboration to evaluate Mymetics' virosomal technology platform through influenza vaccine nearly concludes!

    https://www.mymetics.com/